Expertise in
38
conditions

Dr. Martin E. Gutierrez

Medical Genetics
HMH - John Theurer Cancer Center - Hackensack
92 2nd Street, 
Hackensack, NJ 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
38
conditions
HMH - John Theurer Cancer Center - Hackensack
92 2nd Street, 
Hackensack, NJ 

Overview

Martin Gutierrez is a Medical Genetics provider in Hackensack, New Jersey. Dr. Gutierrez is highly rated in 38 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Colorectal Cancer, and Tissue Biopsy.

His clinical research consists of co-authoring 108 peer reviewed articles and participating in 33 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

Pontificia Universidad Javeriana

Residency

Boston Medical Center

Specialties

Medical Genetics

Licenses

Internal Medicine in NJ

Board Certifications

American Board Of Internal Medicine

Fellowships

National Institutes of Health, NIH

Hospital Affiliations

Hackensack University Medical Center
Jersey Shore University Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MetLife
  • PPO
Nippon Life
  • INSURANCE PLAN
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

HMH - John Theurer Cancer Center - Hackensack
92 2nd Street, Hackensack, NJ 7601.
Other Locations
HMH - John Theurer Cancer Center - Neptune
19 Davis Avenue, Floor 2, Neptune, NJ 7753.

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

31 Clinical Trials

A Phase II Trial of Combination Therapy of Pembrolizumab and Lenvatinib in Patients With Locally Advanced or Metastatic Cervical Cancer
A Phase II Trial of Combination Therapy of Pembrolizumab and Lenvatinib in Patients With Locally Advanced or Metastatic Cervical Cancer
Enrollment Status: Recruiting
Publish Date: October 07, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Lenvatinib
Study Phase: Phase 2
A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: November 24, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Study of VLS-101 in Patients With Solid Tumors
A Phase 2 Study of VLS-101 in Patients With Solid Tumors
Enrollment Status: Terminated
Publish Date: November 10, 2025
Intervention Type: Drug
Study Drug: VLS-101
Study Phase: Phase 2
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2025
Intervention Type: Drug
Study Drugs: TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel
Study Phase: Phase 1
Phase 1 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
Phase 1 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
Enrollment Status: Completed
Publish Date: October 27, 2025
Intervention Type: Drug, Biological
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Enrollment Status: Completed
Publish Date: August 14, 2025
Intervention Type: Drug
Study Drugs: INCAGN01876, Nivolumab, Ipilimumab
Study Phase: Phase 1/Phase 2
A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
Enrollment Status: Completed
Publish Date: June 15, 2025
Intervention Type: Drug
Study Drugs: Docetaxel, GSK3359609, Ipilimumab, Niraparib, Dostarlimab, Cobolimab
Study Phase: Phase 2
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies
Enrollment Status: Completed
Publish Date: June 13, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drug: NC762
Study Phase: Phase 1/Phase 2
A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: December 24, 2024
Intervention Type: Drug
Study Drug: CYT-0851
Study Phase: Phase 1/Phase 2
A Phase I/IIa Open Label, Non-Randomized, Multicenter Study of CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Aenocarcinoma
A Phase I/IIa Open Label, Non-Randomized, Multicenter Study of CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Aenocarcinoma
Enrollment Status: Terminated
Publish Date: December 12, 2024
Intervention Type: Drug, Biological
Study Drugs: CYNK-101, Pembrolizumab, Trastuzumab, Recombinant Human Interleukin-2, Cyclophosphamide, Fludarabine, Mesna
Study Phase: Phase 1/Phase 2
Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)
Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)
Enrollment Status: Terminated
Publish Date: September 23, 2024
Intervention Type: Drug
Study Drugs: ABT-199, Ibrutinib, Rituximab
Study Phase: Phase 1
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: July 25, 2024
Intervention Type: Drug
Study Drug: NC410
Study Phase: Phase 1/Phase 2
Phase I/II Study of Dasatinib and Osimertinib (AZD9291) in Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutations
Phase I/II Study of Dasatinib and Osimertinib (AZD9291) in Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutations
Enrollment Status: Terminated
Publish Date: July 05, 2024
Intervention Type: Drug
Study Drugs: Dasatinib, Osimertinib
Study Phase: Phase 1/Phase 2
A Phase 1, Open-label, Multicenter Study of SYNB1891 Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors and Lymphoma Alone and in Combination With Atezolizumab
A Phase 1, Open-label, Multicenter Study of SYNB1891 Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors and Lymphoma Alone and in Combination With Atezolizumab
Enrollment Status: Terminated
Publish Date: May 03, 2024
Intervention Type: Drug
Study Drugs: SYNB1891, Atezolizumab
Study Phase: Phase 1
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: March 08, 2024
Intervention Type: Drug
Study Drug: NC318
Study Phase: Phase 1/Phase 2
Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies
Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies
Enrollment Status: Terminated
Publish Date: February 05, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)
Enrollment Status: Completed
Publish Date: January 12, 2024
Intervention Type: Drug
Study Drugs: VS-6766, VS-6766+Defactinib
Study Phase: Phase 2
A Phase I, Open-label, Uncontrolled, Multicenter, Dose-escalation Study of M3541 in Combination With Palliative Radiotherapy in Subjects With Solid Tumors
A Phase I, Open-label, Uncontrolled, Multicenter, Dose-escalation Study of M3541 in Combination With Palliative Radiotherapy in Subjects With Solid Tumors
Enrollment Status: Terminated
Publish Date: November 22, 2023
Intervention Type: Drug, Radiation
Study Phase: Phase 1
A Phase 1/2 Study of TPX-0131, A Novel Oral ALK Tyrosine Kinase Inhibitor in Subjects With ALK+ Advanced or Metastatic NSCLC
A Phase 1/2 Study of TPX-0131, A Novel Oral ALK Tyrosine Kinase Inhibitor in Subjects With ALK+ Advanced or Metastatic NSCLC
Enrollment Status: Terminated
Publish Date: May 26, 2023
Intervention Type: Drug
Study Drug: TPX-0131
Study Phase: Phase 1
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: May 01, 2023
Intervention Type: Drug
Study Drugs: SEA-CD40, Pembrolizumab, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 1
A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) In Subjects With Previously Treated Advanced HER2-Positive Solid Tumors
A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) In Subjects With Previously Treated Advanced HER2-Positive Solid Tumors
Enrollment Status: Suspended
Publish Date: April 20, 2023
Intervention Type: Biological
Study Drug: Chimeric antigen receptor T cell therapy
Study Phase: Phase 1
A Phase 2, Open-label Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumor (TET) Progressing After Primary Chemotherapy (SELECT)
A Phase 2, Open-label Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumor (TET) Progressing After Primary Chemotherapy (SELECT)
Enrollment Status: Terminated
Publish Date: February 16, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2
A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women With Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects With Peritoneal Mesothelioma With Recurrence After Prior Chemotherapy
A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women With Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects With Peritoneal Mesothelioma With Recurrence After Prior Chemotherapy
Enrollment Status: Terminated
Publish Date: September 05, 2021
Intervention Type: Drug, Biological
Study Drugs: MCY-M11, Cyclophosphamide
Study Phase: Phase 1
A Prospective, Multinational, Multi-Center, Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy, Safety and Tolerability of siG12D-LODER in Combination With Standard of Care Chemotherapy in the Treatment of Patients With Locally Advanced Pancreatic Cancer
A Prospective, Multinational, Multi-Center, Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy, Safety and Tolerability of siG12D-LODER in Combination With Standard of Care Chemotherapy in the Treatment of Patients With Locally Advanced Pancreatic Cancer
Enrollment Status: Unknown
Publish Date: July 02, 2021
Intervention Type: Drug
Study Drugs: siG12D-LODER, Gemcitabine+Nab-Paclitaxel, Folfirinox
Study Phase: Phase 2
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies
Enrollment Status: Completed
Publish Date: June 01, 2021
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
Phase I/II Trial of Anti-PD-1 Checkpoint Inhibitor Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer
Phase I/II Trial of Anti-PD-1 Checkpoint Inhibitor Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: March 16, 2021
Intervention Type: Radiation, Drug
Study Phase: Phase 1/Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
Enrollment Status: No_longer_available
Publish Date: November 03, 2020
Intervention Type: Drug
A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC
A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC
Enrollment Status: Completed
Publish Date: September 11, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGN-2FF in Patients With Advanced Solid Tumors
A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGN-2FF in Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: July 19, 2019
Intervention Type: Drug
Study Phase: Phase 1
Ib Dose Finding Study of LDE225 Plus Docetaxel/Prednisone in Patients With Advanced or Metastatic Castration Resistant Prostate Cancer Who Experience Disease Progression After Receiving Docetaxel
Ib Dose Finding Study of LDE225 Plus Docetaxel/Prednisone in Patients With Advanced or Metastatic Castration Resistant Prostate Cancer Who Experience Disease Progression After Receiving Docetaxel
Enrollment Status: Withdrawn
Publish Date: June 19, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 30 Less Clinical Trials

108 Total Publications

Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer.
Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer.
Journal: Journal for immunotherapy of cancer
Published: December 23, 2025
Similar Doctors
Expertise in
8
conditions
Dr. Robert J. Desnick
Medical Genetics | Pediatrics
Expertise in
8
conditions
Dr. Robert J. Desnick
Medical Genetics | Pediatrics
1 Gustave L Levy Pl, Box 1498, 
New York, NY 
 (8.4 miles away)
212-659-6700
Languages Spoken:
English

Robert Desnick is a Medical Genetics specialist and a Pediatrics provider in New York, New York. Dr. Desnick is highly rated in 8 conditions, according to our data. His top areas of expertise are Hereditary Coproporphyria, Fabry Disease, Aplasia Cutis Congenita, and Ectodermal Dysplasias.

Expertise in
12
conditions
Dr. Manisha C. Balwani
Medical Genetics
Expertise in
12
conditions
Dr. Manisha C. Balwani
Medical Genetics

Icahn School Of Medicine At Mount Sinai

1428 Madison Ave, 
New York, NY 
 (8.5 miles away)
212-241-6947
Languages Spoken:
English
See accepted insurances

Manisha Balwani is a Medical Genetics provider in New York, New York. Dr. Balwani is highly rated in 12 conditions, according to our data. Her top areas of expertise are Megalencephalic Leukoencephalopathy with Subcortical Cysts, Multiple Sulfatase Deficiency, Gaucher Disease Type 1, and Gaucher Disease Type 2.

Expertise in
4
conditions
Dr. Elaine M. Pereira
Medical Genetics | Pediatrics
Expertise in
4
conditions
Dr. Elaine M. Pereira
Medical Genetics | Pediatrics
3959 Broadway # North718, 
New York, NY 
 (6.7 miles away)
212-305-6731
Languages Spoken:
English
See accepted insurances

Elaine Pereira is a Medical Genetics specialist and a Pediatrics provider in New York, New York. Dr. Pereira is highly rated in 4 conditions, according to our data. Her top areas of expertise are Chromosome 6q Deletion, Chromosome 13q Duplication, Trisomy 13, and Micrognathia.

Frequently Asked Questions about Dr. Martin E. Gutierrez

How do I make an appointment with Dr. Martin E. Gutierrez?

You can book an appointment with Dr. Martin E. Gutierrez by calling their office at 551-996-5863. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Martin E. Gutierrez a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Martin E. Gutierrez is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Martin E. Gutierrez specialize in?

While Dr. Martin E. Gutierrez is a Medical Genetics, they have specific expertise in Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Medical Genetics.

Does Dr. Martin E. Gutierrez participate in research or clinical trials?

Yes. Dr. Martin E. Gutierrez has published 108 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Martin E. Gutierrez's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Martin E. Gutierrez accept my insurance?

Dr. Martin E. Gutierrez accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 551-996-5863 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gutierrez's expertise for a condition
ConditionClose
    View All 23 Distinguished Conditions
    View All 15 Advanced Conditions
    View All 81 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile